Despite these changes, melanoma cells were not growth inhibited in vitro by the VEGF-neutralizing antibody bevacizumab or the VEGFR inhibitor cediranib (Appendix Fig. S2E-F), reinforcing the notion that bevacizumab is unlikely to exert a direct effect on the melanoma cells themselves. This evidence concerns the gene KDR and melanoma.